Alumis Secures $250 Million in Downsized Initial Public Offering

1. Funding Amount: Alumis, an immunology biotech company, has secured $250 million in a downsized initial public offering (IPO).
2. Original Projections: The IPO was smaller than the company's original projections.
3. Phase 3 Development: Alumis is on the cusp of entering Phase 3 of its drug development process.
4. Public Listing: The company went public on Friday, June 28, 2024.
5. Industry Focus: Alumis is focused on developing immunology drugs, a significant area of research in the biotechnology sector.